Advantis Medical Imaging, a leading medical software development company, announced today that the U.S. Food and Drug Administration (FDA) has granted clearance to Advantis Platform, its advanced Brain and Prostate MRI Analysis Software, for commercial distribution.

This is the second FDA clearance for the company following its first clearance in 2021 for the brain MRI solution traded under the name Brainance MD. After integrating its primary brain solution under the newly launched umbrella suite Advantis Platform, the company expanded its software suite capabilities by adding a second module for the processing and visualization of multiparametric prostate MRI exams.

The American Cancer Society estimates 288,300 new prostate cancer cases in the United States for 2023. While 1 man in 8 will be diagnosed with prostate cancer during his lifetime and the shortage of trained radiologists is growing on a yearly basis, the need for data-driven, accessible, and automated tools in today’s modern radiology departments is considered more essential than ever.

View more here